Lilly Completes Acquisition of DICE Therapeutics
Eli Lilly and Company announced the successful completion of its acquisition of DICE Therapeutics, Inc The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology.